Vir Biotechnology, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for VIR, updated each market day.
VIR AI Sentiment
AI predicts Vir Biotechnology, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Vir Biotechnology, Inc. Common Stock
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Sector
Exchange
Market Cap
$1,570,946,012
Cap Tier
Employees
367
Headquarters
SAN FRANCISCO, CA
Listed Since
Oct. 11, 2019
Website
VIR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VIR Volatility
Vir Biotechnology, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
